Table 2.
Characteristics of Studies Included in the Meta-analysis
| Source | Type | Subgroups reported | Ischemic outcome† | Bleeding outcome | Alleles genotyped | Maximum FU (months) | Clopidogrel loading/maintenance doses | Alternate therapy | Alternate loading/maintenance doses | Mean age | Male % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mega 2009,(14) Mega 2009(23) |
RCT | LOF and non-LOF | CVD, MI, CVA | Major or minor | CYP2C19, CYP2C9, CYP2B6, CYP1A2, CYP3A5, CYP1A12 | 15 | 300/75 | Prasugrel | 60/10 | 60 | 72 |
| Wallent in 2010(15) | RCT | LOF and non-LOF | CVD, MI, CVA | Major | CYP2C19 (*2, *3, *4, *5, *6, *7, *8) | 12 | 300–600/75 | Ticagrelor | 180/90 | 63 | 70 |
| Deiman 2016(16) | Non-RCT | LOF only | CVD, MI, CVA, ST, re-PCI | -- | CYP2C19 (*2, *3) | 18 | 300/75 | Prasugrel | --/10 | 67 | 74 |
| Dong 2016(17) | RCT | LOF only | DTH, MI, CVA, revasc | -- | CYP2C19 (*2, *3) | 1 | 600/75 | Ticagrelor | 180/90 | 67 | 80 |
| Ogawa 2016(18) | RCT | LOF and non-LOF | CVD, MI, CVA | Major or minor | CYP2C19 (*2, *3) | 6 | 300/75 | Prasugrel | 20/3.75 | 64 | 81 |
| Zhang 2016(19) | RCT | LOF only | DTH, MI, CVA | Major or minor | CYP2C19 (*2, *3) | 6 | 600/75 | Ticagrelor | 180/90 | 70 | 50 |
| Chen 2017(20) | Non-RCT | LOF only | CVD, MI, CVA | Any bleeding event | CYP2C19 (*2) | 12 | 300/75 | Ticagrelor | --/90 | 60 | -- |
| Cavallari 2018(21) | Non-RCT | LOF and non-LOF | DTH, MI, CVA | -- | CYP2C19 (*2, *3) | 12 | 300/75 | Prasugrel, ticagrelor, high-dose clopidogrel | --/-- | 63 | 67 |
| Lee 2018(22) | Non-RCT | LOF and non-LOF | DTH, MI, CVA, TIA, ST, UA-hosp | Clinically significant | CYP2C19 (*2, *3) | 12 | -- | Prasugrel or ticagrelor | --/-- | -- | |
| Xiong 2015(24) | RCT | LOF only | MACE | Major or minor | CYP2C19 (*2) | 1 | 600/150 | Ticagrelor | 180/90 | 67 | 71 |
| Pereira 2020(7) | RCT | LOF only | CVD, MI, CVA, ST, SRI | Major or minor | CYP2C19 (*2, *3) | 12 | 300–600/75 | Ticagrelor | 180/90 | 62 | 76 |
†
CVD=Cardiovascular-related death, MI=myocardial infarction, CVA=cerebrovascular accident, ST=stent thrombosis, re-PCI=repeat PCI, revasc=revascularization (PCI or CABG), TIA=transient ischemic attack, UA-hosp=hospitalization for unstable angina, MACE=major adverse cardiovascular event, SRI=severe recurrent ischemia.